...
首页> 外文期刊>Anti-Cancer Agents in Medicinal Chemistry >Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
【24h】

Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?

机译:蛋白激酶CK2抑制剂:新兴的抗癌药物?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Protein kinase CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases. A number of structurally unrelated CK2 inhibitors, tested on a variety of cells derived from tumours, including lymphomas, leukaemias, multiple myeloma and prostate carcinoma, display a proapoptotic effect which is roughly proportional to their in vitro inhibitory potency.nnIn the present review we summarize the most recent discovery of potent and selective CK2 inhibitors and their prospective as future anticancer agents.
机译:蛋白激酶CK2是一种普遍存在的,必不可少的,高度多效性的蛋白激酶,其异常高的组成活性被怀疑是其在瘤形成和其他疾病中的致病潜力。在多种源自肿瘤的细胞上测试的许多与结构无关的CK2抑制剂,包括淋巴瘤,白血病,多发性骨髓瘤和前列腺癌,均显示出促凋亡作用,与它们的体外抑制能力大致成正比。有效和选择性CK2抑制剂的最新发现及其作为未来抗癌药的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号